LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity

08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018 a call for expressions of interest, focused on adding value to biomedical research from the I2D2 (Incubation Innovation in Drug Discovery) program. The foundation wanted to contribute in this way to the discovery of drugs for diseases without therapeutic solutions, supporting the best biomedical science on the mechanisms of the disease. Consequently, the I2D2 initiative is meant to promoting innovative projects. As a result of an extremely competitive assessment of 157 projects from Universities, Research Centers and companies, LeadArtis immune-oncology therapeutic project has nominated between the four finalist projects reaching the finalist stage.  
 
LeadArtis is a preclinical stage health biotechnology company located in Madrid (www.leadartis.com) focused on developing tumor targeted multivalent and multispecific immune stimulating antibodies through its unique Trimerbody® technology. The Trimerbodies exhibit excellent antigen binding capacity, functionality and stability.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...